Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial

M. Gordon,Holly Gundacker,Jacqueline Benedetti,John S. Macdonald,Joaquina Baranda,W. J. Levin,Charles D. Blanke,Wafaa Elatre,Peggy Weng,J. Y. Zhou,Heinz-Josef Lenz,Michael F. Press

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial

2013

M. Gordon
Holly Gundacker
Jacqueline Benedetti
John S. Macdonald
Joaquina Baranda
W. J. Levin
Charles D. Blanke
Wafaa Elatre
Peggy Weng
J. Y. Zhou
Heinz-Josef Lenz
Michael F. Press

Background Trastuzumab has been approved for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric carcinoma; however, relatively little is known about the role of HER2 in the natural history of this disease.

Keywords:

Pathology
Clinical trial
Carcinoma
Fluorouracil
Trastuzumab
Gastrectomy
Stomach
Medicine
Immunohistochemistry
Adenocarcinoma
Oncology
Internal medicine
Radiation therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations